<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02175290</url>
  </required_header>
  <id_info>
    <org_study_id>MMC140006CTIL</org_study_id>
    <nct_id>NCT02175290</nct_id>
  </id_info>
  <brief_title>Machado-Joseph Disease in Israel</brief_title>
  <official_title>Machado-Joseph Disease in Israel: Clinical Phenotype and Genotype of a Jew Yemenite Subpopulation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Meir Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Meir Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Machado-Joseph disease (MJD) or spinocerebellar ataxia type 3 (SCA-3) is the most common
      dominant ataxia. The genetic cause of this late-onset degenerative disorder is the expansion
      of a (CAG)n tract located in the exonic region of the ATXN3 gene. In 1994 the first case of
      MJD among the Yemenite Jewish subpopulation living in Israel was published. The puropse of
      this study is to describe the clinical phenotype and genotype of the Yemenite Jewish
      subpopulation with MJD living in Israel
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>clinical phenotype of SCA3 Yemenite Jews patients</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Spinocerebellar Ataxia 3</condition>
  <arm_group>
    <arm_group_label>Spinocerebellar Ataxia 3 Yemenite Jews patients</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Spinocerebellar Ataxia 3 Yemenite Jews patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Spinocerebellar Ataxia 3 Yemenite Jews patients

        Exclusion Criteria:

          -  All others
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Carlos R Gordon, MD;DSc</last_name>
    <phone>972-9-7471581</phone>
    <email>cgordon@post.tau.ac.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Roy Zaltzman, MD;PhD</last_name>
    <phone>972-9-7471581</phone>
    <email>royzaltzman@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Neurology, Meir Medical Center</name>
      <address>
        <city>Kfar-saba</city>
        <zip>44281</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos R Gordon, MD;DSc</last_name>
      <phone>972-9-7471581</phone>
      <email>cgordon@post.tau.ac.il</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 22, 2014</study_first_submitted>
  <study_first_submitted_qc>June 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2014</study_first_posted>
  <last_update_submitted>March 15, 2017</last_update_submitted>
  <last_update_submitted_qc>March 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spinocerebellar Ataxias</mesh_term>
    <mesh_term>Spinocerebellar Degenerations</mesh_term>
    <mesh_term>Machado-Joseph Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

